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OBJECTIVES: To compare prescribing trends and appropriateness of
use of traditional and cyclooxygenase-2 selective (COX-2) nonsteroidal
anti-inflammatory drugs (NSAIDs) by primary care physicians (PCPs)
and specialists.
DESIGN: Retrospective cohort study.
PATIENTS: One thousand five hundred and seventy-six adult patients
continuously enrolled for at least 1 year with an independent practice
association of a University-associated managed care plan who were
started on a traditional NSAID or a COX-2 inhibitor from 1999 to 2002
and received at least 3 separate medication fills.
MEASUREMENTS: Physician specialty was identified from office visits.
Appropriateness of utilization was based on gastrointestinal risk char-
acteristics.
RESULTS: Primary care patients were younger and less likely to have
comorbid conditions. Despite similar GI risk, COX-2 use among pa-
tients seen by PCPs was half that of patients seen by specialists (21% vs
44%, Po.001). While PCPs overused cyclooxygenase-2-specific inhibi-
tors (COX-2s) less often than specialists (19% vs 41%, Po.001), they
also tended to underuse COX-2s in patients who were at increased GI
risk (46% vs 32%, P=.063). This represents a 3-fold and 8-fold differ-
ence in overuse versus underuse for PCPs and specialists, respectively.
CONCLUSIONS: Using COX-2s as a model for physician adoption of
new therapeutic agents, specialists were more likely to use these new
medications for patients likely to benefit but were also significantly
more likely to use them for patients without a clear indication. This
study demonstrates the tension between appropriate adoption of inno-
vative therapies for those individuals who would benefit from their use
and those individuals who would receive no added clinical benefit but
would incur added cost and be placed at increased risk.
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P rescription drug costs continue to escalate at a muchhigher rate than other medical services.1 A substantial
portion of these costs is associated with the introduction of
new, costly medications. The uptake of these new medications
is partially driven by pharmaceutical companies targeting spe-
cialist physicians to become early adopters and promoters of
their drugs in the hope that these physicians will help dissem-
inate information on their use to primary care physicians
(PCPs) and trainees.
Although specialists may provide more appropriate care
for patients presenting with conditions in their specialty then
generalists,2–5 these patients often receive more expensive
medications without additional benefits.4,5 One such group
of medications is the cyclooxygenase-2-specific inhibitors
(COX-2s), which were developed to provide similar pain relief
as traditional non-steroidal anti-inflammatory drugs (NSAIDs)
but with a reduced risk of gastrointestinal (GI) toxicity. Given
the equal efficacy and the higher cost of COX-2s when com-
pared with traditional NSAIDs, their use was recommended for
individuals at risk for NSAID-related adverse GI events. While
the appropriateness of COX-2s has been described, the differ-
ential rate of adoption and appropriateness of use by special-
ists and PCPs has not been reported. Accordingly, the study’s
objectives were to assess the difference between PCPs and spe-
cialists in their (1) rate of adoption of COX-2 selective inhibi-
tors; (2) underuse of COX-2s among high GI risk patients; and
(3) overuse of COX-2s among low GI risk patients
METHODS
We conducted a retrospective cohort study on patients enrolled
with one independent practice association (IPA) of a mid-west-
ern University-associated managed care plan.
Study Population
We identified 38,695 managed care members age 18 or older
who filled prescriptions for NSAIDs or NSAID combinations
between January 1, 1999 and December 31, 2002. We then
restricted the population to those patients who were continu-
ously enrolled in the health care plan for at least 11 months
before their first NSAID prescription, were chronic NSAID us-
ers (i.e., at least 3 prescriptions within any calendar year) and
had seen an IPA physician during the measurement period.
Data Elements
De-identified data obtained from the university health system’s
and managed care organization’s data warehouses included
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patient age, gender, and clinical history. Medications included
NSAIDs, GI protective agents (proton pump inhibitors (PPIs),
and misoprostol), and drugs that increased the risk of GI com-
plications on NSAIDs (glucocorticoids, antiplatelet, and antico-
agulant drugs). Data were compiled on a yearly basis.
Based on the patient’s claims data and electronic problem
summary list, patients were classified as being at an increased
risk for a GI complication (history of upper GI bleed, peptic or
duodenal ulcer; co-therapy with an anticoagulant or cortico-
steroid; or age 70 years or older) or at normal to low risk of a GI
complication.6–8 The study was approved by the University of
Michigan Institutional Review Board.
Identifying New NSAID Prescriptions and
Prescriber Specialty
Patients were considered to have started an NSAID in a meas-
urement year if they had not received a prescription NSAID
within the previous 335 days. Nonsteroidal anti-inflammatory
drug medications were classified as either a traditional NSAID
or a COX-2-specific medication. If a patient received a pre-
scription for both a traditional NSAID and a COX-2-specific
medication in the same year, they were classified as being on a
COX-2 medication.
Physicians were classified as being either a PCP (i.e., phy-
sicians specializing in Family Medicine or General Internal
Medicine) or a specialist (i.e., rheumatologist, orthopedic sur-
geon, or physiatrist). If a patient saw only a PCP or only a spe-
cialist during the measurement year, the patient was assigned
to that group; however, if a patient was treated by both a PCP
and a specialist in the same year, the patient was assigned to
the specialist group because patients naturally ‘‘progress’’
from PCP to specialist. There were a total of 175 PCPs and
111 specialists who wrote first NSAID prescriptions for pa-
tients in this study.
Defining Underuse and Overuse of COX-2s
Patients were divided into low- and high-risk groups based on
their risk for an NSAID related GI complication. Patients at
high risk, who require NSAID therapy, receive significant ben-
efit from using either a COX-2 inhibitor or by combining a
gastroprotective medication with a traditional NSAID. There-
fore, in high-risk patients the use of a traditional NSAID with-
out a gastroprotective agent was considered underuse of a
COX-2. Conversely, patients at no or low risk of a GI compli-
cation from NSAIDs would receive little benefit from a COX-2
and prescribing a COX-2 for such a patient was considered
overuse.
Analysis
We compared characteristics of patients seen by PCPs to those
seen by specialists. Dichotomous variables were analyzed us-
ing Pearson’s w2-test. Ordinal and categorical variables were
compared with the Mann-Whitney rank-sum test. To see
which variables were predictive of COX-2 utilization and over-
use/underuse, we performed bivariate comparisons of all de-
mographic variables, including prescriber type, against type of
NSAID and appropriateness of the prescription. Multiple lo-
gistic regression was used to examine differences between PCP
and specialists for both NSAID utilization and overuse/under-
use of a COX-2 by forcing the prescriber variable into each
model. Data were analyzed using STATA, release 8.0, College
Station, TX.
RESULTS
The characteristics of the 1,576 patients started on a tradition-
al NSAID or a COX-2 inhibitor are shown by physician specialty
in Table 1. Women comprised 58% of the patients. Primary care
patients were younger than those seen by a specialist and were
less likely to be taking either a glucocorticoid or an anticoag-
ulant compared with those cared for by specialists.
Utilization
In 1999, the first year COX-2s were available, 28% of NSAID
prescriptions received by patients seen by a specialist were for
a COX-2 compared with 15% of the prescriptions received by
patients seen only by PCPs. Cyclooxygenase-2 prescribing
peaked at 58% of NSAID prescriptions for patients seen by
specialists in 2000 and at 31% for PCPs in 2001. By 2002,
COX-2 prescribing decreased to 35% and 16% for specialists
and PCPs, respectively. Over the 4-year period, more than
twice as many patients seeing specialists were taking a COX-
2 medication than those cared for only in primary care (44% vs
21%, Po.001) despite similar GI risk between the 2 groups.
Multivariate analysis showed that 6 variables were pre-
dictors of prescribing a COX-2 including a diagnosis of rheu-
matoid arthritis (odds ratio [OR] 2.54, 95% Confidence Interval
Table 1. Characteristics of 1,576 Patients Started on a Traditional or
COX-2 Selective NSAID, by Physician Specialty (1999–2002)







Age (years), median 46 49 o .001
Age group o .01
o 45 years old 48% 39%
45–54 years old 25% 25%
55–64 years old 15% 19%
65 years old 12% 17%
Gender (Female) 59% 56% .35
Musculoskeletal diagnoses
Rheumatoid arthritis 1% 6% o .001
Osteoarthritis 10% 31% o .001
Other musculoskeletal pain 38% 81% o .001




Gastric or duodenal ulcer 8% 6% .45
Upper gastrointestinal bleed 6% 5% .55
High risk for a gastrointestinal
complication from an NSAID
11% 14% .19
History of vascular disease
Coronary artery disease 10% 17% o .001
Other atherosclerosis 23% 26% .29
Peripheral arterial disease 1% 3% .10
Diabetes mellitus 6% 7% .84
Hypertension 23% 23% .77
Gastrointestinal protective medications
Proton pump inhibitor 14% 14% .81
Misoprostol 0% 0% .99
Other medications
Glucocorticoids 0% 2% o 0.001
Anticoagulants 0% 1% .03
NSAID, nonsteroidal anti-inflammatory drugs; COX-2, cyclooxygenase-2.
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[CI] 1.24, 5.22), osteoarthritis (OR 2.49, 95% CI 1.78, 3.48),
other musculoskeletal pain (OR 1.91, 95% CI 1.44, 2.53), gas-
troesophageal reflux disease (OR 1.92, 95% CI 1.36, 2.71), and
age (increasing from an OR 1.82 for patients 45 to 54 years old
to an OR 2.93 for patients age 65 years or older compared with
patients younger than 45 years old). In addition, seeing a spe-
cialist was associated with an almost 2-fold increase in use of a
COX-2 (OR 1.92, 95% CI 1.45, 2.54).
COX-2 Underuse
Patients at an increased risk of an NSAID-related GI complication
would probably benefit from being prescribed either a COX-2
or a traditional NSAID with a gastroprotective agent. While
there was no temporal pattern of underuse of COX-2s, over
40% (n=78) of patients at high GI risk were prescribed neither
treatment (see Table 2). Primary care physicians tended to un-
deruse COX-2s more often than specialists did (46% vs 32%,
P=.063).
Multivariate analysis demonstrated that among patients
at high risk for a GI complication, there was less underuse of
COX-2s for those patients with gastroesophageal reflux dis-
ease (OR 0.25, 95% CI 0.16, 0.57) and more underuse for pa-
tients with diabetes (OR 3.87, 95% CI 1.30, 11.5). There was
no difference by physician specialty.
COX-2 Overuse
As most patients (88%) were at low risk of a GI complication on
NSAIDs, a larger problem with respect to appropriateness was
prescribing COX-2s for patients who would receive limited
benefit but would incur extra cost. More than one-quarter of
low risk patients received COX-2s (see Table 2).
The trend in overuse of COX-2s among patients at low risk
of GI complications was similar to the utilization trend with
specialists peaking at 54% in 2000 compared with 31% among
PCPs in 2001. By 2002, overuse had decreased to 35% and
14% for patients seen by specialists and PCPs, respectively.
This decrease was associated with the institution of prior au-
thorization criteria for COX-2 selective inhibitors within the
managed care plan. Over the 4-year period, PCPs were less
likely to overuse COX-2s compared with specialists (19% vs
41%, Po.001).
Multivariate analysis demonstrated that 5 variables were
significant predictors of overuse: a diagnosis of osteoarthritis
(OR 2.78, 95% CI 1.90, 4.07), other musculoskeletal pain (OR
1.89, 95 CI 1.40, 2.58), or gastroesophageal reflux disease (OR
1.91, 95% CI 1.29, 2.82); increasing age (i.e., compared with
patients younger than age 45, those who were older had a
greater risk of overuse ranging from an OR 1.78 (95% CI 1.27,
2.51) for patients aged 45 to 54 years old to an OR 3.25 (95%
CI 1.90, 5.55) for those age 65 or older); and being seen by a
specialist (OR 2.08, 95% CI 1.54, 2.82).
DISCUSSION
The most appropriate ways to utilize innovations in medicine is
an area open to much debate. Early adopters of medical inno-
vations are more likely to be specialist physicians.9,10 This
makes sense because specialists have advanced training and
education in a rather narrow area of medicine compared with
the average internist. Specialists have more understanding of
a limited number of diseases and are the ones that are per-
forming the diagnostic and therapeutic procedures upon the
most difficult to treat patients. They are often among the key
opinion leaders in their field and, as such, may feel responsible
for pioneering new innovations because of their extended cre-
dentials. However, new innovations often lack scientific vali-
dation with regard to the clinical scenarios that would best call
for their use or application. Newer therapies may not always be
better than existing therapies and may lead to added cost, and
in instances unexpected adverse clinical events.
Regarding the COX-2 inhibitors, the initial decision of
whether or not to use them on a wide scale should have large-
ly been focused on whether the purported GI safety advantage
was worth the substantial incremental cost compared with
equally efficacious traditional NSAIDs. Results from this study
suggest that cost was a less influential factor in the decision
making process for specialists. The appeal of a ‘‘safer’’ drug
accompanied by heightened promotional efforts appears to
have overshadowed the appropriate use of these medications
by specialists who were apparently more concerned about GI
risk. Primary care physicians less frequently prescribed COX-
2s compared with specialists when considering preexisting GI
risk factors, especially among patients at low GI risk where the
use of the more expensive COX-2 agents has little added ben-
efit for the increased cost. Although we evaluated a conven-
ience sample of patients from a single Mid-western managed
care plan, our results are consistent with Sebalt’s report that
among Canadian patients with osteoarthritis 39% of COX-2
prescriptions were for patients that had no identified GI risk
factors and 56% of traditional NSAID prescriptions were for
patients that had at least 1 GI risk factor (where concurrent
gastroprotection or a COX-2 would be recommended).11,12
Given current concerns regarding a possible class effect of
COX-2s on cardiovascular adverse events, the issue has shift-
ed from cost to safety.13–15
Table 2. Appropriateness of Traditional and COX-2 Specific NSAID Prescribing given a Patient’s Risk for A Gastrointestinal Complication While
on an NSAID, by Physician Specialty
GI Risk NSAID Prescribed Total n (%) P-value
Primary care provider Specialist
Low Traditional NSAID 1,029 (74%) 783 (81%) 246 (59%) o .001
Cox-2 358 (26%) 185 (19%) 173 (41%)
High NSAID1GPA or COX-2 111 (59%) 66 (54%) 45 (68%) .06
Traditional NSAID alone 78 (41%) 57 (46%) 21 (32%)
Comparing PCP and specialist.
Text in italics represents inappropriate prescribing practice. COX-2, cyclooxygenase-2 selective; NSAID, nonsteroidal anti-inflammatory drugs; PCP,
primary care physicians.
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There are several limitations in this study. First, we des-
ignated patients as receiving care from a PCP or specialist
based on the physicians they saw and not by which physician
wrote their prescriptions. We believe this better reflects who
was managing the patient. Second, by requiring 3 NSAID pre-
scriptions in a calendar year to be considered a chronic user
and not having information on over-the-counter products, we
underestimate the extent of the problem. Third, since the only
information we had for prescribing physicians was their spe-
cialty, without a unique physician identifier, we cannot statis-
tically adjust for clustering of patients by physician. However,
given that there were 286 different physicians who wrote a first
NSAID prescription for the 1,576 patients in this study, we
suspect this would not significantly alter the findings.
This study demonstrates the tension between appropriate
adoption of innovative therapies for those individuals who would
benefit from their use and those individuals who would receive
no added clinical benefit but would incur added cost and be
placed at increased risk. Those in positions of authority and in-
fluence need to exercise prudence with respect to adopting new
medications and technologies until their appropriate place in
therapy is established. The burden of proof should shift from
physicians feeling they need to defend a decision not to prescribe
new products to one where they can say to pharmaceutical com-
panies ‘‘show me the study’’ proving your product is safe, cost-
effective, and not simply another ‘‘me-too’’ drug.
The authors would like to thank Katherine Young for assisting
with data collection and database management and Myra
Kim, Ph.D., for statistical support. This research was conducted
without support. Financial support for Dr. De Smet’s Fellowship
was provided through an unrestricted educational grant pro-
vided by Pfizer.
REFERENCES
1. Center for American Progress. No Relief for Rising Drug Costs. Avail-
able at: http://www.americanprogress.org/site/pp.asp?c=biJRJ8OVF&
b=83161. Accessed January 31, 2005.
2. Ayanian JZ, Guadagnoli E, McNeil BJ, Cleary PD. Treatment and out-
comes of acute myocardial infarction among patients of cardiologists and
generalist physicians. Arch Intern Med. 1997;157:2570–6.
3. Chin MH, Zhang JX, Merrell K. Specialty differences in the care of older
patients with diabetes. Med Care. 2000;38:131–40.
4. Chin MH, Friedmann PD, Cassel CK, Lang RM. Difference in generalist
and specialist physicians’ knowledge and use of angiotensin-converting
enzyme inhibitors for congestive heart failure. J Gen Intern Med.
1997;12:523–30.
5. Donohoe MT. Comparing generalist and specialty care. Arch Intern Med.
1998;158:1596–608.
6. Fendrick AM, Garabedian-Ruffalo SM. A clinician’s guide to the selec-
tion of NSAID therapy. Pharm Ther. 2002;27:579–82.
7. Peura DA. Gastrointestinal safety and tolerability of nonselective non-
steroidal anti-inflammatory agents and cyclooxygenase-2–selective in-
hibitors. Cleveland Clin J Med. 2002;69(Suppl. 1):31–SI39.
8. National Institute for Clinical Excellence. Technology Appraisal No.
27. Guidance on the Use of Cyclo-oxygenase (COX) II Selective Inhibitors,
Celecoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthritis and
Rheumatoid Arthritis. Available at: http://www.nice.org.uk/pdf/
coxiifullguidance.pdf. Accessed January 31, 2005.
9. Fendrick AM, Schwartz JS. Physicians’ decisions regarding the acqui-
sition of technology. In: Gelijns AC, Dawkins HV, eds. Medical Innova-
tions at the Crossroads. Vol. 4, Adopting New Medical Technology.
Washington, DC: National Academy Press; 1994:71–84.
10. Hirth RA, Fendrick AM, Chernew ME. Specialist and generalist physi-
cians’ adoption of antibiotic therapy to eradicate helicobacter pylori in-
fection. Med Care. 1996;34:204.
11. Sebaldt RJ, Petrie A, Goldsmith CH, Marentette MA. Appropriateness
of NSAID and Coxib prescribing for patients with osteoarthritis by pri-
mary care physicians in ontario: results from the CANOAR study. Am J
Manage Care. 2004;10:742–50.
12. Tannenbaum H, Peloso PMJ, Russel AS, Marlow B. An evidence-based
approach to prescribing NSAIDs in the treatment of osteoarthritis and
rheumatoid arthritis: the second canadian consensus conference. Can J
Clin Pharmacol. 2000;7(Suppl A):4A–16A.
13. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A.
Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ec-
ological study. BMJ. 2004;328:1415–6.
14. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity
with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis
and rheumatoid arthritis. The CLASS study: a randomized controlled
trial. JAMA. 2000;284:1247–55.
15. Bombardier C, Laine L, Reicin A, et al. Comparison of upper GI toxicity
of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J
Med. 2000;343:1520–8.
JGIM 697De Smet et al., Over and Under-utilization of COX-2s
